trending Market Intelligence /marketintelligence/en/news-insights/trending/L0y-Xjp2y1bPNuFDW3aNRg2 content esgSubNav
In This List

Ligand Pharmaceuticals closes acquisition of Crystal Bioscience

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Ligand Pharmaceuticals closes acquisition of Crystal Bioscience

Ligand Pharmaceuticals Inc. closed its acquisition of privately held Crystal Bioscience Inc. for an initial consideration of about $25 million in cash.

Crystal is now a wholly owned subsidiary of Ligand.

According to the merger agreement, Crystal shareholders will also receive up to $10.5 million in milestone payments and revenue sharing from existing licensees for a defined period.